Mycosis Fungoides is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Mycosis Fungoides have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Mycosis Fungoides compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mycosis Fungoides overview
Mycosis fungoides is a rare type of non-Hodgkin lymphoma, specifically a subtype of cutaneous T-cell lymphoma (CTCL), which primarily affects the skin. It is characterized by the abnormal accumulation of malignant T-cells (a type of white blood cell) in the skin, leading to various skin symptoms and, in advanced stages, potential involvement of other organs. Mycosis fungoides is the most common type of CTCL, though it remains relatively rare overall. It typically affects adults, with an average age of onset around 55-60 years, though it can occur at any age, including childhood. The disease progresses slowly over years. Initial symptoms may include red, scaly patches on the skin (known as patches or plaques) that may resemble eczema or psoriasis. These lesions are usually itchy but can vary in appearance. Over time, the disease can progress to more defined tumors, ulcers, or nodules on the skin. In advanced cases, lymph nodes and internal organs may become involved. Diagnosis of mycosis fungoides involves a combination of clinical evaluation, skin biopsy, and sometimes additional tests like blood work, imaging studies (X-rays, CT scans, or PET scans), or a lymph node biopsy to determine the extent of the disease.
For a complete picture of PTSR and LoA scores for drugs in Mycosis Fungoides, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
